Prescriber Criteria Form

Imbruvica 2025 PA Fax 1050-A v2 010125.docx
Imbruvica (ibrutinib)
Coverage Determination

This fax machine is located in a secure location as required by HIPAA regulations.
Complete/review information, sign and date. Fax signed forms to CVS Caremark at **1-855-633-7673.** Please contact CVS Caremark at **1-866-785-5714** with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Imbruvica (ibrutinib).

Drug Name:
Imbruvica (ibrutinib)

Patient Name:		
Patient ID:		
Patient DOB:	**Patient Phone:**	
Prescriber Name:		
Prescriber Address:		
City:	**State:**	**Zip:**
Prescriber Phone:	**Prescriber Fax:**	
Diagnosis:	**ICD Code(s):**	

Please circle the appropriate answer for each question.			
1	Does the patient have any of the following diagnoses: A) chronic lymphocytic leukemia (CLL), B) small lymphocytic lymphoma (SLL)? [If yes, then skip to question 4.]	Yes ◯	No ◯
2	Does the patient have a diagnosis of mantle cell lymphoma? [If no, then skip to question 7.]	Yes ◯	No ◯
3	Will the requested drug be used as subsequent therapy? [If no, then skip to question 5.]	Yes ◯	No ◯
4	Has the patient experienced an inadequate treatment response, intolerance, or does the patient have a contraindication to Calquence (acalabrutinib)? [No further questions.]	Yes ◯	No ◯
5	Will the requested drug be used in combination with rituximab as pretreatment to induction therapy with RHyperCVAD (rituximab, cyclophosphamide, vincristine, doxorubicin, and dexamethasone) regimen? [If yes, then no further questions.]	Yes ◯	No ◯
6	Will the requested drug be used as aggressive induction therapy? [No further questions.]	Yes ◯	No ◯

7	Does the patient have any of the following diagnoses: A) Waldenstrom's macroglobulinemia, B) lymphoplasmacytic lymphoma? [If yes, then no further questions.]	Yes ◯	No ◯
8	Does the patient have a diagnosis of marginal zone lymphoma (including extranodal marginal zone lymphoma of the stomach, extranodal marginal zone lymphoma of nongastric sites, nodal marginal zone lymphoma, and splenic marginal zone lymphoma)? [If no, then skip to question 10.]	Yes ◯	No ◯
9	Will the requested drug be used as second-line or subsequent therapy? [No further questions.]	Yes ◯	No ◯
10	Does the patient have a diagnosis of chronic graft-versus-host disease (cGVHD)? [If no, then skip to question 12.]	Yes ◯	No ◯
11	Did the patient fail one or more lines of systemic therapy? [No further questions.]	Yes ◯	No ◯
12	Does the patient have a diagnosis of hairy cell leukemia? [If no, then skip to question 14.]	Yes ◯	No ◯
13	Will the requested drug be used as a single agent for disease progression? [No further questions.]	Yes ◯	No ◯
14	Does the patient have a diagnosis of primary central nervous system lymphoma? [If no, then skip to question 17.]	Yes ◯	No ◯
15	Is the disease relapsed or refractory? [If yes, then no further questions.]	Yes ◯	No ◯
16	Will the requested drug be used for induction therapy as a single agent? [No further questions.]	Yes ◯	No ◯
17	Does the patient have any of the following diagnoses: A) diffuse large B-cell lymphoma, B) high-grade B-cell lymphoma, C) human immunodeficiency virus (HIV)-related B-cell lymphoma? [If no, then skip to question 21.]	Yes ◯	No ◯
18	Will the requested drug be used as a single agent? [If no, then no further questions.]	Yes ◯	No ◯
19	Is the disease relapsed or refractory? [If no, then no further questions.]	Yes ◯	No ◯
20	Will the requested drug be used as second-line or subsequent therapy? [No further questions.]	Yes ◯	No ◯
21	Is the requested drug being used for post-transplant lymphoproliferative disorders? [If no, then no further questions.]	Yes ◯	No ◯
22	Has the patient received prior chemoimmunotherapy?	Yes ◯	No ◯

Comments:	_____

By signing this form, I attest that the information provided is accurate and true as of this date and that the documentation supporting this information is available for review if requested by the health plan.
Prescriber (or Authorized) Signature: _____ Date:_____